CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
NucleomaxX (contains uridine)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00471614
NCT00471614Phase 2Completed

Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV

National Center for Complementary and Integrative Health (NCCIH)·interventional·Posted May 10, 2007·Updated May 16, 2012

In Brief

A Phase 2 clinical trial evaluating NucleomaxX (contains uridine) for HIV Infections and 2 related conditions. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether uridine supplementation will improve insulin sensitivity and overall carbohydrate metabolism in HIV-positive subjects who are currently undergoing treatment with antiretroviral regimens containing stavudine or zidovudine and who have evidence of impaired mitochondrial function and insulin resistance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 10, 2007
Enrollment StartApr 1, 2007
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.1 years ago

Interventions

NucleomaxX (contains uridine)drug

Escalated doses of NucleomaxX tid